News

IPF Envisia Genomic Classifier Validated in New Study, Veracyte Announces

Veracyte has published new data confirming the analytical validity of its Envisia Genomic Classifier to help diagnose idiopathic pulmonary fibrosis (IPF). Its study, “Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia,” appeared in the journal BMC Pulmonary Medicine. The 190-gene Envisia Genomic Classifier helps physicians distinguish between IPF and…

Chicago Bears’ Jordan Howard to Wear PF-Branded Cleats in Dec. 3 Game

In memory of his father, who lived many years with pulmonary fibrosis (PF), Chicago Bears’ Jordan Howard will wear luminous blue-and-green cleats to support the Pulmonary Fibrosis Foundation (PFF) when he takes to the field Sunday, Dec. 3. The PFF is chosen by Howard for the second year in…

Registry-based Research Has Started, Pulmonary Fibrosis Foundation Announces at Summit

The first research projects using data from the Pulmonary Fibrosis Foundation’s Patient Registry are under way, the foundation announced at an international conference in Nashville that bears its name. A record 895 people attended the Pulmonary Fibrosis Foundation Summit Nov. 9-11, where doctors and scientists discussed the latest developments in the field.

New York’s Montefiore Einstein Center Starts Lung Transplant Program

The Montefiore Einstein Center for Heart & Vascular Care has started a lung transplant program, joining an exclusive group of premier surgical programs in New York. Surgeons at the center will focus on people with conditions like pulmonary fibrosis, cystic fibrosis, emphysema and rheumatic diseases. The United Network for…

Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds

Despite the availability of approved antifibrotic treatments for idiopathic pulmonary fibrosis (IPF), many patients in Europe do not receive them, partly due to a lack of awareness by physicians or a preference for a “wait and watch” approach in people with stable or milder disease, a survey reveals. Better education…

Inhibiting Inflammation-promoting Enzyme Slows Lung Tissue Scarring, Mouse Study Shows

Inhibiting an inflammation-promoting enzyme known as sialidase slowed lung tissue scarring in mice with pulmonary fibrosis, a study shows. The research indicated that sialidase inhibitors, such as Tamiflu, could be used to treat idiopathic pulmonary fibrosis, or IPF. The underlying causes of fibrosis in diseases such as IPF and asthma are still…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums